VACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NATIONAL INSTITUTES OF HEALTH NIAID

Contract Value

Not provided

Codes & Classification
Solicitation Number

75N98026D00085

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Classification Code

AN12

Additional Details
Set Aside

None

Place of Performance

Rockville, Maryland, UNITED STATES

SourceSAM
The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), has issued an award notice for an Indefinite Delivery, Indefinite Quantity (IDIQ) contract pertaining to vaccine and other biologic manufacturing services for infectious diseases. The guaranteed minimum award amount is $10,000, establishing a baseline commitment for the contract. This procurement is classified under NAICS code 541715, which covers Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology). The associated Product Service Code is AN12, indicating a focus on research and development activities related to medical and biological products. The place of performance is Rockville, Maryland, underscoring the contract’s alignment with NIH’s research infrastructure and proximity to key federal health agencies. The primary objective of this contract is to secure manufacturing services for vaccines and other biologics that address infectious diseases. The scope encompasses the development, production, and potentially the scale-up of biologic products, supporting NIH’s mission to advance public health through innovative research and product development. Contractors are expected to deliver high-quality manufacturing capabilities, adhere to rigorous scientific and regulatory standards, and support the agency’s ongoing and future infectious disease initiatives. The contracting entity is the NIH NIAID, operating under the Department of Health and Human Services. The primary point of contact for this opportunity is Hamed Hassanzadeh Makou, who can be reached at [email protected] or by phone at 301-761-7466. The notice remains active and is accessible via the SAM.gov portal, providing transparency and ongoing updates for interested parties. This award notice does not specify set-aside requirements or special considerations, nor does it include additional attachments or documents. Contractors evaluating this opportunity should note the federal nature of the procurement, the research and development focus, and the expectation for robust manufacturing capabilities in the field of infectious disease biologics. The contract’s structure as an IDIQ allows for flexibility in task orders and deliverables over its lifecycle, ensuring alignment with evolving public health needs. Overall, this procurement represents a strategic investment by NIH NIAID in advancing vaccine and biologic manufacturing for infectious diseases, with the intent to foster innovation, support public health preparedness, and enable rapid response to emerging threats.